Effect of Bevacizumab Combined with Afatinib on Serum VEGF in NSCLC with EGFR Mutation and Prognosis Analysis
Objective To explore the therapeutic effect of bevacizumab combined with afatinib on vascular endothelial growth factor(VEGF)and prognosis in patients with non-small cell lung cancer(NSCLC)with epidermal growth factor receptor(EGFR)mutation.Methods A total of 70 NSCLC patients with EGFR mutation admitted to Binzhou Central Hospital from June 2019 to June 2021 were randomly selected as the study objects,and were divided into single group(treated with afatinib)and combination group(treated with bevacizumab combined afatinib)according to the method of random number table,with 35 cases in each group.The short-term effect,tumor marker level,vascular growth factor level,survival prognosis and incidence of adverse reactions were compared between the two groups.Results The objec-tive response rate of the combination group was 68.57%,which was higher than that of the single group(45.71%),the difference was statistically significant(χ2=5.777,P<0.05).After treatment,the levels of cytokeratin 19 fragment anti-gen 21-1,cancer antigen 125,carcinoembryonic antigen,serum basic fibroblast growth factor,vascular endothelial growth factor and platelet-derived growth factor were reduced in both groups,those of the combination group were lower than those of the single group,the differences were statistically significant(all P<0.05).After 30 months of follow-up,the median progression-free survival time and median overall survival time in the combination group were higher than those in the single group,the differences were statistically significant(both P<0.05).There was no statisti-cally significant difference in the incidences of adverse reactions between the two groups(all P>0.05).Conclusion The combination of bevacizumab and afatinib in the treatment of EGFR mutation NSCLC can achieve significant effec-tiveness include inhibition of angiogenesis,improve patient's prognosis and provide patients with better treatment op-tions and chances of survival.
万方数据
维普
